FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1506551608> ?p ?o ?g. }

• W1506551608 endingPage "124" @default.
• W1506551608 startingPage "116" @default.
• W1506551608 abstract "• Inhibition of cholesteryl ester transfer protein (CETP) is a potential new mechanism for the treatment of dyslipidaemia. Anacetrapib is a novel CETP inhibitor in development. Warfarin is a commonly prescribed anticoagulant that has a narrow therapeutic index. A drug interaction study for warfarin with a novel CETP inhibitor is expected to be helpful in defining dosing regimens. WHAT THIS STUDY: ADDS • This is the first study to show that there is no clinically meaningful pharmacokinetic interaction between anacetrapib and warfarin. The single dose pharmacokinetics and pharmacodynamics of orally administered warfarin were not meaningfully affected by multiple dose administration of anacetrapib, indicating that anacetrapib does not affect CYP 2C9 clinically. Thus, no dosage adjustment for warfarin is necessary when co-administered with anacetrapib.Anacetrapib is currently being developed for the treatment of dyslipidaemia. Since warfarin, an anticoagulant with a narrow therapeutic index, is expected to be commonly prescribed in this population, a drug interaction study was conducted.In a randomized, open-label, two-period fixed-sequence design, 12 healthy male subjects received two different treatments (treatment A followed by treatment B). In treatment A, a single oral dose of 30 mg warfarin (3 × 10 mg Coumadin(TM) ) was administered on day 1. After a washout interval, subjects began treatment B, where they were given daily 100 mg doses of anacetrapib (1 × 100 mg) beginning on day -14 and continuing through day 7, with concomitant administration of 30 mg warfarin (3 × 10 mg) on day 1. All anacetrapib and warfarin doses were administered with a standard low fat breakfast. After warfarin concentrations and prothrombin time were measured, standard pharmacokinetic, pharmacodynamic and statistical (linear mixed effects model) analyses were applied.Anacetrapib was generally well tolerated when co-administered with warfarin in the healthy males in this study. The geometric mean ratios (GMRs) for warfarin + anacetrapib : warfarin alone and 90% confidence interval (CIs) for warfarin AUC((0-∞)) were 0.94 (0.90, 0.97) for the R(+) warfarin enantiomer and 0.93 (0.87, 0.98) for the S(-) warfarin enantiomer, both being contained in the interval (0.80, 1.25), supporting the primary hypothesis of the study. The GMRs warfarin + anacetrapib : warfarin alone and 90% CIs for the statistical comparison of warfarin C(max) were 1.01 (0.97, 1.05) for both the R(+) warfarin and the S(-) warfarin enantiomers, and were also contained in the interval (0.80, 1.25). The GMR (warfarin + anacetrapib : warfarin alone) and 90% CI for the statistical comparison of INR AUC((0-168 h)) was 0.93 (0.89, 0.96).The single dose pharmacokinetics and pharmacodynamics of orally administered warfarin were not meaningfully affected by multiple dose administration of anacetrapib, indicating that anacetrapib does not affect CYP 2C9 clinically. Thus, no dosage adjustment for warfarin is necessary when co-administered with anacetrapib." @default.
• W1506551608 created "2016-06-24" @default.
• W1506551608 creator A5001481373 @default.
• W1506551608 creator A5002603430 @default.
• W1506551608 creator A5006724848 @default.
• W1506551608 creator A5011021512 @default.
• W1506551608 creator A5012834818 @default.
• W1506551608 creator A5021441570 @default.
• W1506551608 creator A5029610349 @default.
• W1506551608 creator A5035258562 @default.
• W1506551608 creator A5044409463 @default.
• W1506551608 creator A5057369590 @default.
• W1506551608 creator A5059590015 @default.
• W1506551608 creator A5061641302 @default.
• W1506551608 date "2012-06-11" @default.
• W1506551608 modified "2023-10-17" @default.
• W1506551608 title "Lack of a meaningful effect of anacetrapib on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects" @default.
• W1506551608 cites W1565329824 @default.
• W1506551608 cites W1747652400 @default.
• W1506551608 cites W1965398926 @default.
• W1506551608 cites W1978297207 @default.
• W1506551608 cites W1978430613 @default.
• W1506551608 cites W1985989412 @default.
• W1506551608 cites W1991728240 @default.
• W1506551608 cites W2005332332 @default.
• W1506551608 cites W2018747988 @default.
• W1506551608 cites W2046630860 @default.
• W1506551608 cites W2061250936 @default.
• W1506551608 cites W2065976317 @default.
• W1506551608 cites W2068602483 @default.
• W1506551608 cites W2068634821 @default.
• W1506551608 cites W2075656550 @default.
• W1506551608 cites W2090464684 @default.
• W1506551608 cites W2108297214 @default.
• W1506551608 cites W2142003978 @default.
• W1506551608 cites W2144414775 @default.
• W1506551608 cites W2159449551 @default.
• W1506551608 cites W2164900475 @default.
• W1506551608 cites W2166606079 @default.
• W1506551608 cites W2335822722 @default.
• W1506551608 cites W4297754350 @default.
• W1506551608 doi "https://doi.org/10.1111/j.1365-2125.2012.04171.x" @default.
• W1506551608 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3394135" @default.
• W1506551608 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22243494" @default.
• W1506551608 hasPublicationYear "2012" @default.
• W1506551608 type Work @default.
• W1506551608 sameAs 1506551608 @default.
• W1506551608 citedByCount "8" @default.
• W1506551608 countsByYear W15065516082012 @default.
• W1506551608 countsByYear W15065516082013 @default.
• W1506551608 countsByYear W15065516082014 @default.
• W1506551608 countsByYear W15065516082016 @default.
• W1506551608 countsByYear W15065516082017 @default.
• W1506551608 countsByYear W15065516082018 @default.
• W1506551608 countsByYear W15065516082019 @default.
• W1506551608 crossrefType "journal-article" @default.
• W1506551608 hasAuthorship W1506551608A5001481373 @default.
• W1506551608 hasAuthorship W1506551608A5002603430 @default.
• W1506551608 hasAuthorship W1506551608A5006724848 @default.
• W1506551608 hasAuthorship W1506551608A5011021512 @default.
• W1506551608 hasAuthorship W1506551608A5012834818 @default.
• W1506551608 hasAuthorship W1506551608A5021441570 @default.
• W1506551608 hasAuthorship W1506551608A5029610349 @default.
• W1506551608 hasAuthorship W1506551608A5035258562 @default.
• W1506551608 hasAuthorship W1506551608A5044409463 @default.
• W1506551608 hasAuthorship W1506551608A5057369590 @default.
• W1506551608 hasAuthorship W1506551608A5059590015 @default.
• W1506551608 hasAuthorship W1506551608A5061641302 @default.
• W1506551608 hasBestOaLocation W15065516081 @default.
• W1506551608 hasConcept C111113717 @default.
• W1506551608 hasConcept C112705442 @default.
• W1506551608 hasConcept C126322002 @default.
• W1506551608 hasConcept C141071460 @default.
• W1506551608 hasConcept C19831878 @default.
• W1506551608 hasConcept C2776301958 @default.
• W1506551608 hasConcept C2777288759 @default.
• W1506551608 hasConcept C2778205648 @default.
• W1506551608 hasConcept C2779161974 @default.
• W1506551608 hasConcept C2780035454 @default.
• W1506551608 hasConcept C71924100 @default.
• W1506551608 hasConcept C97320921 @default.
• W1506551608 hasConcept C98274493 @default.
• W1506551608 hasConceptScore W1506551608C111113717 @default.
• W1506551608 hasConceptScore W1506551608C112705442 @default.
• W1506551608 hasConceptScore W1506551608C126322002 @default.
• W1506551608 hasConceptScore W1506551608C141071460 @default.
• W1506551608 hasConceptScore W1506551608C19831878 @default.
• W1506551608 hasConceptScore W1506551608C2776301958 @default.
• W1506551608 hasConceptScore W1506551608C2777288759 @default.
• W1506551608 hasConceptScore W1506551608C2778205648 @default.
• W1506551608 hasConceptScore W1506551608C2779161974 @default.
• W1506551608 hasConceptScore W1506551608C2780035454 @default.
• W1506551608 hasConceptScore W1506551608C71924100 @default.
• W1506551608 hasConceptScore W1506551608C97320921 @default.
• W1506551608 hasConceptScore W1506551608C98274493 @default.
• W1506551608 hasIssue "1" @default.
• W1506551608 hasLocation W15065516081 @default.
• W1506551608 hasLocation W15065516082 @default.

• next